$12.800
+0.060 (+0.47%)At close
ELOX Comparative Benchmarking
In the context of the broader market, ELOX competes directly with industry leaders such as ONCY and INKT. With a market capitalization of $50.26M, it holds a significant position in the sector. When comparing efficiency, ELOX's gross margin of N/A stands against ONCY's N/A and INKT's N/A. Such benchmarking helps identify whether Eloxx Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.
Eloxx Pharmaceuticals Inc Financial Performance
Eloxx Pharmaceuticals reported a net loss of $4.5 million in Q2 2026, translating to a loss of $0.66 per share, which is a significant increase from a net loss of $1.9 million in the same quarter last year. The company's current ratio improved to 3.74, indicating a strong liquidity position.
Financials
Related articles
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.